Waldenstrom's Macroglobulinemia News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenstr öm’s Macroglobulinemia
HORSHAM, Pa., August 27, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 27, 2018 Category: Drugs & Pharmacology Source Type: news

IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and variou... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, Waldenström's Macroglobulinemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib/Rituximab Yields Prolonged PFS in Waldenstr öm Macroglobulinemia
Bryant FurlowJun 4, 2018In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

IMBRUVICA ® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 2, 2018 Category: Pharmaceuticals Source Type: news

Patience Needed: WM Is Incurable, but Survival Is Long Patience Needed: WM Is Incurable, but Survival Is Long
Management of the rare lymphoma Waldenstrom ' s macroglobulinemia (WM) takes patience and practice to maximize longevity and keep symptoms at bay over the long haul.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Phase 3 Study Evaluating IMBRUVICA ® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 5, 2017 Category: Pharmaceuticals Source Type: news

NICE recommends use of Janssen ’s Imbruvica for Waldenstr ö m ’s macroglobulinaemia
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Janssen Pharmaceutical ’s Imbruvica (ibrutinib) on the Cancer Drugs Fund (CDF) to treat adults with a type of non-Hodgkin lymphoma called Waldenstr ö m ’s m… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Ibrutinib'Remarkable' in Waldenstrom's Macroglobulinemia Ibrutinib'Remarkable' in Waldenstrom's Macroglobulinemia
Single-agent ibrutinib is highly active in refractory Waldenstrom ' s macroglobulinemia, with results that ' eclipse other treatment options, ' says an editorialist.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ibrutinib: Indication of added benefit in one of three therapeutic indications
No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 2, 2016 Category: Science Source Type: news

Ibrutinib: Indication of added benefit in one of three therapeutic indications
(Institute for Quality and Efficiency in Health Care) No added benefit proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2016 Category: Global & Universal Source Type: news

Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 6, 2015 Category: Pharmaceuticals Source Type: news

CURE Media Group Adds International Waldenstrom’s Macroglobulinemia...
Partnership expands outreach and information for patients suffering from rare cancer.(PRWeb October 13, 2015)Read the full story at http://www.prweb.com/releases/CUREAdvocacy/IWMF/prweb13016892.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 14, 2015 Category: Pharmaceuticals Source Type: news

AbbVie’s Imbruvica obtains European approval to treat blood cancer WM
AbbVie has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat patients with Waldenstrom's macroglobulinemia (WM), a rare and slow-growing blood cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 12, 2015 Category: Pharmaceuticals Source Type: news

Ibrutinib Gets High Marks for Waldenstrom's Macroglobulinemia
(MedPage Today) -- Data supporting recent FDA approval appear in print. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 11, 2015 Category: Hematology Source Type: news